

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT COOPERATION WITH SBM ON LOCALIZATION OF DIAGNOSTIC EQUIPMENT FOR DRY EYE

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that, previously, the Group entered into certain license agreements (the “**License Agreements**”) with SBM Sistemi S.r.l. (“**SBM**”), a company established in Italy, regarding the localization of two diagnostic devices for dry eye. Pursuant to the License Agreements, with effect from March 1, 2023, the Group is granted with the exclusive right to use and exploit certain diagnostic technologies of SBM and to design, manufacture, assemble and sell two diagnostic devices of SBM, namely Gaush iDea and OS1000 Topographer, in the Chinese mainland, Hong Kong and Macau. The term of the License Agreements is five years commenced from the completion of localization registration of the diagnostic devices.

The Directors believe that the cooperation with SBM is an important milestone of the Company’s strategy on localization of ophthalmic devices. The cooperation with SBM reflects upstream suppliers’ trust in the Company and their recognition of the Company’s reputation in the ophthalmology industry of China. The Directors are of the view that the Company is able to work together with long-term partners to deal with and solve market problems, and gradually strengthen in-depth cooperation with partners for mutual development.

With the mission “technology creates bright vision (科技締造光明視界)”, the Company will continue to work closely with its partners, to focus on the needs of customers and create value for customers, and to contribute to the development of the ophthalmology industry in China.

ABOUT GAUSH IDEA AND OS1000 TOPOGRAPHER

Gaush iDea Ocular Surface Interferometer (“**Gaush iDea**”) and OS1000 Corneal Topographer (“**OS1000 Topographer**”) were launched by SBM in Europe in 2018 and 2022 respectively.

Gaush iDea is a comprehensive, fast, quantitative and intelligent analyzer of dry eye and ocular surface. Gaush iDea has three imaging techniques and eleven functions, and it can complete routine examination of dry eye in three minutes and provide physicians with solid basis for diagnosis and treatment.

OS1000 Topographer is a precise diagnostic device integrating comprehensive analysis of dry eye and ocular surface. OS1000 Topographer can provide physicians with more parameters of ocular surface and tear film to facilitate comprehensive diagnosis and evaluation.

ABOUT SBM

SBM is an Italian company founded in 1984 and has dedicated itself to the field of optics for 30 years and has made many achievements in the research and development of optical measurement devices. Since SBM launched its first dry eye detection device in 2014, it continued to innovate, and launched Gaush iDea and OS1000 Topographer in 2018 and 2022 respectively.

To the best knowledge of the Directors, SBM is not a connected person of the Company within the meaning of the Rules Governing Listing of Securities on The Stock Exchange of Hong Kong Limited as of the date of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, March 1, 2023

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Zhang Jianjun, Mr. Liu Xinwei and Mr. Zhao Xinli as executive Directors, Dr. David Guowei Wang and Mr. Shi Long as non-executive Directors, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.